Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q13797

UPID:
ITA9_HUMAN

ALTERNATIVE NAMES:
Integrin alpha-RLC

ALTERNATIVE UPACC:
Q13797; Q14638

BACKGROUND:
The Integrin alpha-9/beta-1 complex, identified by its affinity for the sequence A-E-I-D-G-I-E-L in cytotactin, serves as a receptor for multiple extracellular matrix proteins. This specificity underlines its critical function in mediating cell-extracellular matrix interactions, which are fundamental to tissue repair, immune response, and developmental processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Integrin alpha-9 opens up new avenues for therapeutic intervention. Given its central role in mediating crucial cellular functions, targeting this protein could lead to innovative treatments for diseases where cell adhesion and migration are factors.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.